Exercise for Clients Taking an Anti-Obesity Medication.
作者信息
Rogers Renee J
机构信息
University of Kansas Medical Center, Department of Internal Medicine, Division of Physical Activity and Weight Management.
出版信息
ACSMs Health Fit J. 2024 May-Jun;28(3):21-26. doi: 10.1249/fit.0000000000000959.
Abstract
摘要
相似文献
1
Exercise for Clients Taking an Anti-Obesity Medication.
ACSMs Health Fit J. 2024 May-Jun;28(3):21-26. doi: 10.1249/fit.0000000000000959.
2
Medication-Assisted Weight Loss in the Age of Obesity.
J Psychosoc Nurs Ment Health Serv. 2017 Aug 1;55(8):21-26. doi: 10.3928/02793695-20170718-02.
3
Effectiveness and persistence of anti-obesity medications (liraglutide 3 mg, lorcaserin, and orlistat) in a real-world primary care setting.
Fam Pract. 2023 Dec 22;40(5-6):629-637. doi: 10.1093/fampra/cmac141.
4
Pharmacotherapy for the Treatment of Overweight and Obesity in Children, Adolescents, and Young Adults in a Large Health System in the US.
Front Endocrinol (Lausanne). 2020 May 13;11:290. doi: 10.3389/fendo.2020.00290. eCollection 2020.
5
Navigating coverage: A qualitative study exploring the perceived impact of an insurance company policy to discontinue coverage of antiobesity medication.
Obes Pillars. 2024 Jul 22;11:100120. doi: 10.1016/j.obpill.2024.100120. eCollection 2024 Sep.
6
Incretin-Based Therapies and Lifestyle Interventions: The Evolving Role of Registered Dietitian Nutritionists in Obesity Care.
J Acad Nutr Diet. 2025 Mar;125(3):408-421. doi: 10.1016/j.jand.2024.10.023. Epub 2024 Nov 7.
7
Medications as adjunct therapy for weight loss: approved and off-label agents in use.
J Am Diet Assoc. 2005 Jun;105(6):948-59. doi: 10.1016/j.jada.2005.03.010.
8
Evidence-based weight loss interventions: Individualized treatment options to maximize patient outcomes.
Diabetes Obes Metab. 2021 Feb;23 Suppl 1:50-62. doi: 10.1111/dom.14200. Epub 2020 Nov 24.
9
The Benefit of Healthy Lifestyle in the Era of New Medications to Treat Obesity.
Diabetes Metab Syndr Obes. 2024 Jan 15;17:227-230. doi: 10.2147/DMSO.S447582. eCollection 2024.
10
Long-term drug treatment for obesity: a systematic and clinical review.
JAMA. 2014 Jan 1;311(1):74-86. doi: 10.1001/jama.2013.281361.
引用本文的文献
1
A Remotely Delivered GLP-1RA-Supported Specialist Weight Management Program in Adults Living With Obesity: Retrospective Service Evaluation.
JMIR Form Res. 2025 Jun 30;9:e72577. doi: 10.2196/72577.
2
Health and Well-Being Coaching Adjuvant to GLP-1 Induced Weight Loss.
Am J Lifestyle Med. 2024 Nov 19:15598276241302273. doi: 10.1177/15598276241302273.
3
Knowledge and Perception of Anti-obesity Medications Among Primary Healthcare Center Visitors in Jeddah, Saudi Arabia in 2024: An Analytical Cross-Sectional Study.
Cureus. 2024 Aug 30;16(8):e68240. doi: 10.7759/cureus.68240. eCollection 2024 Aug.
本文引用的文献
1
The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities.
Curr Obes Rep. 2023 Dec;12(4):453-473. doi: 10.1007/s13679-023-00534-z. Epub 2023 Dec 2.
2
Physical activity in the new era of antiobesity medications.
Obesity (Silver Spring). 2024 Feb;32(2):234-236. doi: 10.1002/oby.23930. Epub 2023 Oct 17.
3
New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics.
Annu Rev Med. 2023 Jan 27;74:125-139. doi: 10.1146/annurev-med-043021-014919.
4
Tirzepatide Once Weekly for the Treatment of Obesity.
N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4.
5
Impact of weight loss with diet or diet plus physical activity on cardiac magnetic resonance imaging and cardiovascular disease risk factors: Heart Health Study randomized trial.
Obesity (Silver Spring). 2022 May;30(5):1039-1056. doi: 10.1002/oby.23412.
6
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
JAMA. 2022 Jan 11;327(2):138-150. doi: 10.1001/jama.2021.23619.
7
Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.
N Engl J Med. 2021 May 6;384(18):1719-1730. doi: 10.1056/NEJMoa2028198.
8
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
JAMA. 2021 Apr 13;325(14):1414-1425. doi: 10.1001/jama.2021.3224.
9
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10.
10
Feasibility of Integration of Yoga in a Behavioral Weight-Loss Intervention: A Randomized Trial.
Obesity (Silver Spring). 2021 Mar;29(3):512-520. doi: 10.1002/oby.23089. Epub 2021 Feb 2.
Zotero 插件